News & Updates
Filter by Specialty:
Infliximab, adalimumab biosimilars effective, safe in paediatric IBD
The use of biosimilars of infliximab (IFX) and adalimumab (ADA) is both safe and effective in children with inflammatory bowel disease (IBD), inducing high rates of failure-free survival with a low incidence of adverse events, according to a study presented at the 2022 Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN 2022).
Infliximab, adalimumab biosimilars effective, safe in paediatric IBD
27 Jun 2022
Specific carbohydrate diet may improve symptoms for some IBD patients
A specific carbohydrate diet (SCD) and a modified SCD (MSCD) demonstrate inconsistent effectiveness for the improvement of symptoms in inflammatory bowel disease (IBD), with some patients benefitting and others not, reports a study.
Specific carbohydrate diet may improve symptoms for some IBD patients
26 Jun 2022
Colorectal cancer alters gut microbiome
Patients with colorectal cancer (CRC) have a substantially altered gut microbiome, characterized by changes in bacterial composition, according to a recent Singapore study. Of note, these alterations persist even after surgery.
Colorectal cancer alters gut microbiome
24 Jun 2022
Aminosalicylate use more common among older than younger IBD patients
Use of medication is markedly different among older patients with inflammatory bowel disease (IBD), with more aminosalicylate monotherapy and less antitumour necrosis factor monotherapy than younger patients, according to a US study.